| Literature DB >> 32242145 |
Lorinda Turner1, Julieta Galante2,3, Maris Vainre4,5, Jan Stochl6,7,8, Géraldine Dufour9,10, Peter B Jones6,7.
Abstract
Psychological distress persisting for weeks or more promotes pro-inflammatory immune dysregulation, a risk factor for a range of chronic diseases. We have recently shown that mindfulness training reduces distress among university students. Here we present an exploratory trial to study immune dysregulation in a cohort of students who were exposed to progressively greater stress as the exam period approached, and to explore whether mindfulness training mitigated this dysregulation. Healthy University of Cambridge students were randomised to join an 8-week mindfulness course (N = 27), or to mental health support as usual (N = 27). Psychological distress, immune cell proportions, cytokines, CRP and serum cortisol were measured at baseline and during the exam period. Increased distress was associated with statistically significant increases in the proportion of B cells, regardless of trial arm (*p = 0.027). There were no other associations between any of the measured parameters, distress or mindfulness. Our finding that the proportion of B cells increases with psychological distress supports the findings of other studies. However, we found no evidence that mindfulness training is able to buffer the effects of psychological distress on healthy participants' immune system. In order to detect these effects, should they exist, larger randomised trials will be required.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32242145 PMCID: PMC7118166 DOI: 10.1038/s41598-020-62274-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1CONSORT 2010 flow diagram. *Reasons explained in text. Abbreviations: min = minimum, MSS = Mindfulness Skills for Students; SAU = support as usual.
Participants’ characteristics.
| Control | Intervention | Total | |||||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||
| Gender | Females | 20 | 74.07% | 18 | 66.67% | 38 | 70.37% |
| Age | 17–21 | 11 | 40.74% | 13 | 48.15% | 24 | 44.44% |
| 22–30 | 12 | 44.44% | 12 | 44.44% | 24 | 44.44% | |
| 31+ | 4 | 14.81% | 2 | 7.41% | 6 | 11.11% | |
| Nationality | UK or European Union | 16 | 59.26% | 20 | 74.07% | 36 | 66.67% |
| Ethnicity | Asian | 6 | 23.08% | 5 | 20.00% | 11 | 21.57% |
| Black | 1 | 3.85% | 0 | 0.00% | 1 | 1.96% | |
| Mixed | 2 | 7.69% | 0 | 0.00% | 2 | 3.92% | |
| Other | 0 | 0.00% | 3 | 12.00% | 3 | 5.88% | |
| White | 17 | 65.38% | 17 | 68.00% | 34 | 66.67% | |
| Disability | Yes | 1 | 3.70% | 4 | 14.81% | 5 | 9.26% |
| Degree | Undergraduate | 12 | 44.44% | 12 | 44.44% | 24 | 44.44% |
| Masters | 1 | 3.70% | 3 | 11.11% | 4 | 7.41% | |
| MPhil | 5 | 18.52% | 5 | 18.52% | 10 | 18.52% | |
| PhD | 9 | 33.33% | 7 | 25.93% | 16 | 29.63% | |
| Last Year | Yes | 14 | 51.85% | 13 | 48.15% | 27 | 50.00% |
| BMI | Underweight | 0 | 0% | 2 | 9% | 2 | 4% |
| Healthy weight | 14 | 56% | 15 | 65% | 29 | 60% | |
| Overweight | 7 | 28% | 5 | 22% | 12 | 25% | |
| Obese | 4 | 16% | 1 | 4% | 5 | 10% | |
Outcome values for all time points and groups, and statistical tests for pre-post changes on the total sample.
| Baseline | Exam term | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean | SD | Median | Range | N | Mean | SD | Median | Range | ||
| CORE-OM | MSS | 26 | 0.93 | 0.49 | 0.87 | 0.18 to 2.06 | 25 | 1.01 | 0.61 | 0.85 | 0.09 to 2.29 |
| Control | 27 | 0.9 | 0.54 | 0.76 | 0.03 to 0.2.32 | 27 | 1.05 | 0.52 | 1 | 0.06 to 2.06 | |
| Total | 53 | 0.91 | 0.51 | 0.82 | 0.03 to 2.32 | 52 | 1.03 | 0.56 | 0.96 | 0.06 to 2.29 | |
| Cortisol | MSS | 26 | 313.65 | 123.48 | 325 | 109 to 518 | 22 | 324.55 | 201.82 | 300 | 121 to 992 |
| Control | 27 | 353.96 | 199.15 | 303 | 118 to 896 | 25 | 289.32 | 168.97 | 205 | 119 to 781 | |
| Total | 53 | 334.19 | 166.06 | 316 | 109 to 896 | 47 | 305.81 | 183.87 | 228 | 119 to 992 | |
| IL-8 | MSS | 26 | 8.43 | 3.29 | 7.9 | 3.9 to 17.6 | 22 | 9.35 | 3.86 | 8.15 | 5.1 to 21.4 |
| Control | 27 | 7.24 | 2.54 | 6.6 | 3 to 14.4 | 25 | 8.85 | 3.67 | 8.2 | 4.3 to 21.6 | |
| Total* | 53 | 7.82 | 2.97 | 7 | 3 to 17.6 | 47 | 9.08 | 3.72 | 8.2 | 4.3 to 21.6 | |
| TNF-α | MSS | 26 | 1.78 | 0.43 | 1.75 | 1 to 2.7 | 22 | 2.12 | 0.7 | 1.85 | 1.4 to 4.2 |
| Control | 27 | 1.74 | 0.39 | 1.7 | 1.2 to 3.1 | 25 | 1.97 | 0.43 | 1.8 | 1.5 to 3.5 | |
| Total** | 53 | 1.76 | 0.4 | 1.7 | 1 to 3.1 | 47 | 2.04 | 0.57 | 1.8 | 1.4 to 4.2 | |
| CRP | MSS | 26 | 1.84 | 2.16 | 1.3 | 0.5 to 11.7 | 22 | 1.32 | 1.23 | 0.75 | 0.5 to 4.4 |
| Control | 27 | 2.15 | 1.89 | 1.4 | 0.9 to 8.8 | 25 | 1.78 | 2.24 | 1 | 0.5 to 9.4 | |
| Total* | 53 | 2 | 2.01 | 1.4 | 0.5 to 11.7 | 47 | 1.57 | 1.83 | 1 | 0.5 to 9.4 | |
| % CD4+ T Lymphocytes | MSS | 24 | 0.62 | 0.1 | 0.64 | 0.33 to 0.75 | 20 | 0.6 | 0.09 | 0.62 | 0.45 to 0.73 |
| Control | 26 | 0.65 | 0.11 | 0.66 | 0.39 to 0.82 | 25 | 0.59 | 0.1 | 0.59 | 0.33 to 0.76 | |
| Total* | 50 | 0.63 | 0.1 | 0.65 | 0.33 to 0.82 | 45 | 0.6 | 0.1 | 0.62 | 0.33 to 0.76 | |
| % CD8+ T Lymphocytes | MSS | 24 | 0.23 | 0.1 | 0.21 | 0.14 to 0.58 | 20 | 0.28 | 0.08 | 0.26 | 0.18 to 0.47 |
| Control | 26 | 0.19 | 0.08 | 0.17 | 0.09 to 0.5 | 25 | 0.29 | 0.08 | 0.29 | 0.15 to 0.5 | |
| Total*** | 50 | 0.21 | 0.09 | 0.18 | 0.09 to 0.58 | 45 | 0.29 | 0.08 | 0.28 | 0.15 to 0.5 | |
| % CD19+ B Lymphocytes | MSS | 24 | 0.15 | 0.09 | 0.14 | 0.03 to 0.37 | 19 | 0.22 | 0.08 | 0.21 | 0.05 to 0.34 |
| Control | 26 | 0.16 | 0.07 | 0.16 | 0.05 to 0.29 | 25 | 0.25 | 0.09 | 0.23 | 0.08 to 0.4 | |
| Total*** | 50 | 0.16 | 0.08 | 0.16 | 0.03 to 0.37 | 44 | 0.23 | 0.08 | 0.23 | 0.05 to 0.4 | |
| % CD14+ Monocytes | MSS | 24 | 0.35 | 0.12 | 0.33 | 0.12 to 0.6 | 18 | 0.42 | 0.1 | 0.4 | 0.22 to 0.61 |
| Control | 26 | 0.38 | 0.1 | 0.37 | 0.16 to 0.58 | 24 | 0.45 | 0.12 | 0.47 | 0.22 to 0.61 | |
| Total** | 50 | 0.37 | 0.11 | 0.36 | 0.12 to 0.6 | 42 | 0.43 | 0.11 | 0.42 | 0.22 to 0.66 | |
| % NK cells | MSS | 24 | 0.25 | 0.13 | 0.21 | 0.09 to 0.63 | 18 | 0.29 | 0.13 | 0.29 | 0.11 to 0.49 |
| Control | 26 | 0.18 | 0.09 | 0.15 | 0.06 to 0.44 | 24 | 0.24 | 0.11 | 0.22 | 0.08 to 0.54 | |
| Total** | 50 | 0.21 | 0.11 | 0.2 | 0.06 to s0.63 | 42 | 0.26 | 0.12 | 0.23 | 0.08 to 0.54 | |
*p < 0.05; **p < 0.01; ***p < 0.001. All p values are adjusted for multiple comparisons. Abbreviations: MSS: Mindfulness Skills for Students course; NK: natural killer.
Summary of random intercept models looking at fixed effects for change in distress.
| Outcome (unit) | Regression coefficienta | Standard error | P-valueb |
|---|---|---|---|
| Cortisol (nmol.L) | −45.67 | 34.69 | 0.95 |
| CRP (mg.L) | 0.52 | 0.33 | 0.77 |
| IL-8 (pg.ml) | 0.48 | 0.63 | 1 |
| TNFa (pg.ml) | −0.07 | 0.10 | 1 |
| % CD4+ T Lymphocytes | 0.04 | 0.02 | 0.40 |
| % CD8+ T Lymphocytes | −0.03 | 0.02 | 0.77 |
| % CD19+ B Lymphocytes | 0.05 | 0.02 | |
| % CD14+ Monocytes | 0.03 | 0.02 | 0.95 |
| % NK cells | −0.002 | 0.02 | 1 |
aAdjusted mean difference. bAll p values are adjusted for multiple comparisons. Abbreviations: NK: natural killer.
Figure 2Relationship between mean differences of CORE-OM and mean differences of CD19. To obtain the mean differences, the distances of each CORE and CD19 data point from the mean CORE and CD19 at their respective time points were calculated.
Summary of random intercept models looking at fixed effects for trial arm (ITT analysis).
| Outcome (unit) | Regression coefficienta | Standard error | P-valueb |
|---|---|---|---|
| Cortisol (nmol.L) | −2.34 | 40.92 | 1 |
| CRP (mg.L) | −0.40 | 0.49 | 1 |
| IL-8 (pg.ml) | 0.94 | 0.84 | 1 |
| TNFa (pg.ml) | 0.08 | 0.11 | 1 |
| %CD4+ T Lymphocytes | −0.01 | 0.03 | 1 |
| %CD8+ T Lymphocytes | 0.02 | 0.02 | 1 |
| %CD19+ B Lymphocytes | −0.02 | 0.02 | 1 |
| %CD14+ Monocytes | −0.03 | 0.03 | 1 |
| %NK cells | 0.07 | 0.03 | 0.27 |
aAdjusted mean difference. bAll p values are adjusted for multiple comparisons. Abbreviations: ITT: intention-to-treat; NK: natural killer.